Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 32298202

Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2020 Sep 1
First author
Frey NV

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Frey NV
      type
      Author
    2. name
      Gill S
      type
      Author
    3. name
      Hexner EO
      type
      Author
    4. name
      Schuster S
      type
      Author
    5. name
      Nasta S
      type
      Author
    6. name
      Loren A
      type
      Author
    7. name
      Svoboda J
      type
      Author
    8. name
      Stadtmauer E
      type
      Author
    9. name
      Landsburg DJ
      type
      Author
    10. name
      Mato A
      type
      Author
    11. name
      Levine BL
      type
      Author
    12. name
      Lacey SF
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Frey NV
      type
      Author
    2. name
      Gill S
      type
      Author
    3. name
      Hexner EO
      type
      Author
    4. name
      Schuster S
      type
      Author
    5. name
      Nasta S
      type
      Author
    6. name
      Loren A
      type
      Author
    7. name
      Svoboda J
      type
      Author
    8. name
      Stadtmauer E
      type
      Author
    9. name
      Landsburg DJ
      type
      Author
    10. name
      Mato A
      type
      Author
    11. name
      Levine BL
      type
      Author
    12. name
      Lacey SF
      type
      Author
    bibliography ids
    1. nci-bib-b32acf1d088e2e15185332ef
    book metadata
    content sha256
    12e5c0403d235a82b5a3c07659acb4e1e21cf2ed7bd84172a900c88d56a6a686
    document type
    citation
    dois
    1. 10.1200/JCO.19.03237
    electronic publication date
    display
    2020 Apr 16
    precision
    day
    year
    2020
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:32298202
    immutable id
    pubmed:32298202@12e5c0403d235a82b5a3c07659acb4e1e21cf2ed7bd84172a900c88d56a6a686
    journal
    abbreviation
    J Clin Oncol
    issn electronic
    1527-7755
    issn print
    0732-183X
    issue
    25
    name
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    nlm unique id
    8309333
    pages
    2862-2871
    volume
    38
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      32298202
      provenance
      batch id
      40d9eae1f1d369f13109
      provider
      NCBI PubMed ESummary
      record sha256
      c3fb7ba1d26d30d8dbedb04160ed6d3e7e8956be8497f13009f93b937084098c
      response sha256
      03fa1567b6babd78281d8ec4529596b9d4953c2c4ac23257dca371d609645ba9
      retrieved at
      2026-09-09T23:47:52.637547+00:00
      publication date
      display
      2020 Sep 1
      precision
      day
      year
      2020
      publication types
      1. Clinical Trial, Phase II
      2. Journal Article
      3. Randomized Controlled Trial
      4. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/32298202/
      title
      Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia.

      Preserved source evidence · Not medical advice